Arcellx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

On Sunday, Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma ...

Oppenheimer laid out five “aspirational” potential takeover targets in biotech heading into the annual JPMorgan Health Care Conference. “We ...

Arcellx, Inc. (NASDAQ:ACLX – Get Free Report)’s share price rose 5.1% on Wednesday after UBS Group raised their price target on the stock from $106.00 to $114.00.UBS Group currently has a buy ...

Cell therapy developer Arcellx contends its lead program could be a safer alternative to currently available CAR T-treatments for multiple myeloma, noting that its previously reported preliminary ...

Arcellx (NASDAQ:ACLX – Get Free Report)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a research note issued to investors on Monday,Benzinga reports.

In the latest quarter, 14 analysts provided ratings for Arcellx (NASDAQ:ACLX), showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ...

Arcellx, Inc. (NASDAQ:ACLX), a U.S. biopharmaceutical company valued at $4.51 billion, has been making waves in the biotechnology sector with its innovative approach to cell therapy for multiple ...

In the last three months, 14 analysts have published ratings on Arcellx (NASDAQ:ACLX), offering a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments ...

Arcellx, Inc. (NASDAQ:ACLX), a U.S. biopharmaceutical company valued at $4.57 billion, has been making waves in the cell therapy space with its innovative approach to treating multiple myeloma and ...